ILD Learning Center Content Directory

Integrated metabolomic profiling identifies citrate as novel diagnostic biomarker for Anti-MDA5-Positive dermatomyositis

November 2025

News

CONCLUSION: Our study underscores the pivotal role of DHEAS and citrate as promising diagnostic biomarkers of IIM and anti-MDA5 + DM, respectively, providing novel insights into the pathogenic mechanism and potential therapeutic targets.

Artificial Intelligence-Driven Discovery of Pyrazolo[1,5-<em>a</em>]pyrimidine Derivatives as Novel Phosphodiesterase 4 Inhibitors for Treating Idiopathic Pulmonary Fibrosis

November 2025

News

Phosphodiesterase 4 (PDE4) has been validated as a promising therapeutic target for idiopathic pulmonary fibrosis (IPF), a devastating interstitial lung disease lacking really effective therapeutic drugs, particularly exacerbated in the post-COVID-19 era. Herein, we reported the discovery of 13c, a novel pyrazolo[1,5-a]pyrimidine-based PDE4 inhibitor, via an innovative artificial intelligence (AI)-driven virtual screening approach integrated with structure-based design. The cocrystal analysis of...

Factors associated with the development of postoperative pneumonia in lung cancer surgery patients with perioperative oral management

November 2025

News

CONCLUSIONS: The results of this study indicated that the incidence of postoperative pneumonia following perioperative oral function management was maintained as low as that reported previously. The importance of dental intervention in the perioperative period was also elucidated. A high number of patients who developed postoperative pneumonia despite these interventions had fewer than 20 remaining teeth, suggesting that more attention should be paid to perioperative oral management, including...

Andamertinib in Advanced Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results from the Phase 2 KANNON Study

November 2025

News

CONCLUSIONS: Andamertinib at 240 mg once daily demonstrated efficacy with a manageable safety profile in previously treated patients with EGFR ex20ins-mutant NSCLC.

Targeted next-generation sequencing of bronchoalveolar lavage fluid for pathogen detection in connective tissue disease-related pulmonary infections

November 2025

News

The study aims to assess the clinical value of targeted next-generation sequencing of bronchoalveolar lavage fluid (BALF-tNGS) in pulmonary infection associated with connective tissue diseases (CTDs) and characterize the infection profiles in these patients. CTD patients undergoing bronchoscopy with BALF-tNGS between January 2022 to July 2025 were enrolled. tNGS results were compared with conventional microbiological tests (CMTs). Logistic regression identified risk factors for monomicrobial...

Ganetespib as an inhibitor of heat shock protein 90 alleviates pulmonary fibrosis by inhibiting the Wnt/β-catenin signaling pathway

November 2025

News

Pulmonary fibrosis, a progressive interstitial lung disease with rising global incidence, currently has limited therapeutic options. Ganetespib is a potent HSP90 inhibitor, has shown anti-fibrotic potential in liver models, but its mechanism in pulmonary fibrosis remains unclear. In this study, we demonstrated that Ganetespib significantly suppressed HSP90 expression in vitro and in vivo and attenuated fibroblast-myofibroblast transformation. In vivo experiments, utilizing protein expression...

Aetiologic diagnosis of thoracic granulomatous diseases: a retrospective multicentre study in South-Central China

November 2025

News

CONCLUSIONS: Most thoracic granulomas arise from mycobacterial or fungal infection, while sarcoidosis is the leading non-infectious cause. Thoracoscopy and surgical biopsy show superior diagnostic yields, and special staining aids differentiation of fungal aetiologies. Findings support a multidisciplinary approach to improve diagnostic accuracy.

Characterisation of patients with antifibrotic-treated non-idiopathic pulmonary fibrosis progressive pulmonary fibrosis: a retrospective real-life study

November 2025

News

CONCLUSIONS: In our cohort, the underlying diagnoses and immunomodulatory treatments received significantly differed from those in the phase III licensing trial. More patients received nintedanib at a reduced dose than at a full dose, despite limited evidence of its efficacy and effectiveness. This highlights the large gap in evidence and the need for additional real-world data.

The Italian Society for Rheumatology guidelines for the treatment of patients with rheumatoid arthritis and interstitial lung disease

November 2025

News

CONCLUSIONS: These guidelines represent a fundamental step towards improving the health management of patients with rheumatological diseases in Italy by providing specific and evidence-based guidelines for the management of RA-ILD. Their use is intended to promote health and reduce the burden of morbidity and mortality in this vulnerable population.

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

November 2025

News

Anti-MDA5 autoantibodies are critical biomarkers for dermatomyositis (DM), amyopathic dermatomyositis (CADM), and polymyositis (PM), particularly in identifying patients at risk of rapidly progressive interstitial lung disease (RP-ILD). Early detection of these autoantibodies is essential to improve patient outcomes, as delayed diagnosis often leads to poor prognoses. Currently, radioimmunoassay is the gold standard for detecting anti-MDA5, but its use is limited by high costs, lengthy...